ARID1A and glioblastoma: Kaplan–Meier survival curve analysis showed that the median survival of ARID1A KD GBM mice was significantly shorter, whereas TMZ treatment ARID1A KD mice had a further shortened median survival of 25 days compared to 31 days for control mice (Figure 6B).